AdvanCell
Develops lead-212 targeted alpha therapies to treat cancer
$315MSeries D
Role not disclosedLoading investors…
Activity from announced rounds
Develops lead-212 targeted alpha therapies to treat cancer
Designs cancer care systems around the body's natural upright position